This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Camden-Clark Memorial Hospital Selects Eclipsys To Meet Clinical Excellence And Business Transformation Goals

Eclipsys Corporation (NASDAQ: ECLP), The Outcomes Company ®, today announced that Camden-Clark Memorial Hospital (Camden-Clark), a 273-bed community hospital located in Parkersburg, WV, has signed a multimillion dollar agreement to support clinical excellence and business transformation goals. New client Camden-Clark will pursue becoming a top performing hospital by replacing legacy competitor technology with the entire Sunrise Enterprise™ integrated suite of clinical and revenue cycle solutions, along with Eclipsys’ Enterprise Performance Management solution suite. Once complete, the sweeping electronic health record (EHR) and administrative software initiative will serve to improve care team efficiency, clinical decision making, while enhancing administrative processes, patient safety and throughput. The community hospital also will be positioned to achieve the expected “Meaningful Use” requirements of the American Reinvestment and Recovery Act (ARRA) of 2009. To that end, Camden-Clark will use Eclipsys’ “speed to value” implementation approach to accelerate the activation timeframe to help meet the specified timeline requirements of ARRA in order to maximize stimulus payment opportunities.

Achieving ARRA Guidelines and Improving Outcomes across the Care Continuum

“Our hospital chose Eclipsys because they share our vision to achieve top decile performance in patient quality and satisfaction and are committed to help us achieve this vision,” said Michael A. King, president and chief executive officer of Camden-Clark Memorial Hospital. “This initiative will equip our physicians with real-time access to up-to-date patient information and maximum clinical effectiveness. This investment also will improve each caregiver’s ability to make more informed decisions. The technology tools will enable a more collaborative, streamlined care environment across all our departments and disciplines. Most important, the patients and the community we serve will receive the ultimate benefit of improved healthcare for their lifetime.”

Key Solutions to Meeting Expected ARRA “Meaningful Use”

New technology solutions include Eclipsys’ leading computerized physician order entry (CPOE) system and other integrated clinical software solutions that document and automate care at the bedside, critical care units, laboratory, radiology department and the emergency room. An integrated pharmacy system will set the stage for closed loop medication administration processes and expedite more accurate handoffs between clinicians and pharmacist to reduce the chance for medication errors. To further support patient safety, Camden-Clark selected Eclipsys’ Knowledge-Based Medication Administration™ to help ensure the right patient receives the right medication via a handheld device caregivers will use to scan medication bar codes at the bedside. Web portal technology also will give Camden-Clark physicians secure, Internet access to patient information, such as test results and vital signs to enable quicker, more informed patient care decisions, regardless of whether the physician is at the hospital, home or office.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs